Duchenne muscular dystrophy (DMD)

sarepta building
Favicon Fierce Pharma

Sarepta, despite key trial flop, will seek full nod for DMD meds

Sarepta’s Vyondys 53 and Amondys 45 failed to show a statistically significant difference versus placebo on a key measurement of DMD patient mobility.
Angus Liu Nov 4, 2025 7:56am
NVS

Novartis pays $12B for late-stage dystrophy biotech Avidity

Oct 26, 2025 4:01pm
Manila folder with CONFIDENTIAL printed on it in red

Capricor responds to cell therapy snub, disputes FDA’s concerns

Sep 9, 2025 11:44am
boardroom

Keros shakes up leadership structure to go all in on DMD drug

Aug 7, 2025 6:15am
sarepta building
Favicon Fierce Pharma

FDA backtracks on Sarepta's gene therapy Elevidys in DMD

Jul 28, 2025 6:02pm
Redbrick building with Sarepta name and logo
Favicon Fierce Pharma

FDA contemplates pulling Sarepta’s Elevidys from market

Jul 18, 2025 3:10pm